Convidecia is under clinical development by CanSino Biologics and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Registration is open for faculty to attend the Westwood Lecture Series on Jan. 28. Suresh Mittal, Distinguished Professor of Virology in the College of Veterinary Medicine, will present ...

Manufacturers are investing in key recombinant vaccines and improving product pipelines, driving growth in the market.

The CDC recommends disinfecting things with a chlorine bleach solution or one of the products listed on this Environmental ...

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Concentrated efforts on the part of our government and WHO have completely eradicated smallpox and reduced the incidence of ...

He emphasized that in its current form, HMPV is unlikely to cause severe infections, even amid global concerns of a coronavirus-like outbreak.

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral ...

This report segments the global cancer vaccines market by technology (recombinant cancer vaccines, viral vector & DNA cancer vaccines, whole cell cancer vaccines, and others), type (preventative ...

It is hard to overestimate the importance of antibodies in the frameworks of biotechnology and pharmaceutical industries.